Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Ranitidine bismuth citrate with clarithromycin for the eradication of Helicobacter pylori and for ulcer healing
Helicobacter, Volume 2, No. 3, Year 1997
Notification
URL copied to clipboard!
Description
Background. In a pilot study, ranitidine bismuth citrate (RBC; Pylorid, Tritec) in coprescription with clarithromycin achieved a Helicobacter pylori eradication rate (based on 13C urea breath test alone) of 83%. The aim of the current study was to validate this finding by using three diagnostic tests and a larger group of H. pylori-positive patients with active duodenal ulcer. Methods. In a blinded study, 95 patients were given either 4 weeks of treatment with RBC, 400 mg bid, alone (RBC400, n = 31) or RBC, 400 mg bid or 800 mg bid, in coprescription with clarithromycin, 250 mg qid for 14 days, followed by 14 days of RBC, 400 mg bid, alone (RBC400+CLAR and RBC800+CLAR, respectively; n = 32 for each). Rates of ulcer healing at week 4 and of H. pylori eradication (assessed by antral and corpus urease tests and histology and by 13C urea breath test) at week 8 were compared, together with the incidence of adverse events. Results. All three regimens were effective at duodenal ulcer healing and were tolerated well. The coprescription regimens gave significantly higher observed H. pylori eradication rates (82% and 74% for RBC400+ CLAR and RBC800+CLAR) compared with RBC400 (0%; p<.001). Conclusions. RBC in dual therapy with clarithromycin provides excellent H. pylori eradication therapy and is an effective duodenal ulcer healing drug. © Blackwell Science, Inc.
Authors & Co-Authors
Pounder, Roy E.
United Kingdom, London
The Royal Free Hospital
Wyeth, John W.
United Kingdom, London
The Royal Free Hospital
Duggan, Annette E.
United Kingdom, Brentford
Glaxosmithkline Plc.
Bailey, Robert James
Canada, Edmonton
Royal Alexandra Hospital, Edmonton
Louw, Japie A.
South Africa, Observatory
Groote Schuur Hospital
Ohlin, Bo
Sweden, Karlskrona
Centralsjukhuset
Statistics
Citations: 6
Authors: 6
Affiliations: 5
Identifiers
Doi:
10.1111/j.1523-5378.1997.tb00074.x
ISSN:
10834389
Study Design
Cohort Study